NA-Semax

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is NA-Semax?

NA-Semax (N-Acetyl Semax Amidate) is a modified form of Semax, a synthetic heptapeptide analogue of ACTH(4-10) — the biologically active fragment of adrenocorticotropic hormone. Semax itself was developed at the Institute of Molecular Genetics in Moscow and has been registered as a pharmaceutical in Russia since 1994 for neurological and cognitive applications.[1]

The NA-Semax modification adds an N-terminal acetyl group and a C-terminal amide to the native Semax sequence (Met-Glu-His-Phe-Pro-Gly-Pro). These modifications are designed to increase enzymatic stability and potentially enhance blood-brain barrier penetration, extending the functional duration beyond that of unmodified Semax.[2]

Compound Profile

What Does NA-Semax Actually Do?

NA-Semax’s biological activity is inferred primarily from the Semax research literature, as dedicated studies on the N-acetyl amide modification are extremely limited. Semax research demonstrates neuroprotective, nootropic, and immunomodulatory properties through ACTH-related signalling pathways.[1][2]

The parent compound Semax has shown neuroprotective effects in multiple experimental models. Recent research demonstrated Semax’s ability to compensate for gene expression disruption in rat brain following experimental ischaemic stroke, modulating transcriptomic profiles toward recovery patterns within 24 hours of insult.[3] Whether the NA modification enhances these effects, merely extends their duration, or alters the pharmacological profile is not established by direct comparative research.

How NA-Semax Works

The mechanism of action is understood through Semax research, which has identified several molecular pathways:[1][2]

BDNF and neurotrophic signalling: Semax has been shown to upregulate brain-derived neurotrophic factor (BDNF) and other neurotrophic factors. This BDNF-enhancing effect is one of the most consistently reported findings across Semax studies and is considered a key mechanism underlying its neuroprotective and cognitive-enhancing properties.

Gene expression modulation: Large-scale transcriptomic studies have demonstrated that Semax and ACTH-like peptides modulate immune gene expression patterns in brain regions following ischaemia. These peptides appear to compensate for stroke-induced transcriptomic disruption, restoring expression patterns toward baseline.[3][4]

Calcium signalling: Recent research has demonstrated that Semax affects intracellular calcium dynamics in rat brain neurons, suggesting effects on neuronal excitability and signalling at the cellular level.[5]

Opioid receptor interaction: Novel research has identified that Semax targets the mu opioid receptor gene Oprm1, promoting deubiquitination and functional recovery in spinal cord injury models. This previously unrecognised mechanism suggests broader pharmacological activity than initially understood.[6]

Antidepressant and anti-stress effects: Comparative studies have demonstrated antidepressant-like and anti-stress effects of Semax in forced swim and chronic stress paradigms, with efficacy comparable to other ACTH-derived peptides.[7]

The N-acetylation and C-amidation modifications in NA-Semax are standard peptide chemistry approaches to enhance metabolic stability. The acetyl group protects against aminopeptidase degradation at the N-terminus, while the amide protects against carboxypeptidase degradation at the C-terminus.

Longevity / Healthy Aging Context

Semax-derived peptides are investigated within longevity and healthy aging research primarily through the lens of neuroprotection and cognitive preservation. Age-related neurodegenerative decline involves many of the same pathways that Semax modulates — BDNF reduction, neuroinflammation, oxidative stress, and impaired calcium homeostasis.[1]

The neuroprotective effects demonstrated in ischaemic stroke models — gene expression compensation, immune modulation, calcium signalling regulation — are relevant to age-related neurological decline, though the connection is inferential rather than directly demonstrated in aging populations.[3][4]

No clinical longevity studies have been conducted with NA-Semax specifically. The longevity context is extrapolated from acute neuroprotection data in injury models. Compare with Semax, Selank, and Cortexin for related neuroprotective profiles, or see the Longevity / Healthy Aging goal page.

Recovery & Sleep Context

Semax’s demonstrated effects on neurological recovery from ischaemia position it within the recovery research context. The ability to modulate post-ischaemic gene expression toward recovery patterns and reduce inflammatory cascades in brain tissue suggests relevance to neurological recovery processes.[3][4]

The anti-stress and antidepressant-like effects observed in animal models could theoretically influence recovery through stress-axis modulation. Chronic stress impairs recovery processes, and ACTH-derived peptides that modulate HPA axis signalling may indirectly support recovery by reducing stress-mediated interference.[7]

Direct evidence linking NA-Semax to recovery outcomes or sleep quality does not exist. The recovery context for NA-Semax specifically is entirely inferred from parent compound Semax data. See the Recovery & Sleep goal page for broader context.

NA-Semax Benefits

• Enhanced stability: The N-acetyl and C-amide modifications are designed to improve enzymatic resistance compared to unmodified Semax, potentially extending functional duration.
• BDNF upregulation (from Semax data): The parent compound consistently demonstrates BDNF enhancement in preclinical models — one of the most reproducible findings in the Semax literature.[1]
• Neuroprotective gene modulation: Semax compensates for ischaemia-induced transcriptomic disruption, a mechanism with broad relevance to neuroprotection.[3][4]
• Novel opioid receptor mechanism: Recent discovery of mu opioid receptor gene targeting adds a previously unrecognised mechanistic dimension to Semax pharmacology.[6]
• Multi-pathway activity: Unlike single-target compounds, Semax-derived peptides modulate neurotrophic, immune, and calcium signalling pathways simultaneously.[1][5]

NA-Semax Side Effects

No dedicated safety studies for NA-Semax have been conducted. Side effect considerations are inferred from Semax research and general peptide pharmacology:

• ACTH-related effects: As an ACTH(4-10) analogue, theoretical concerns about HPA axis modulation exist, though Semax at studied concentrations did not produce significant cortisol or ACTH-like endocrine effects.
• Nasal irritation: If administered intranasally (the most common Semax delivery route), local mucosal irritation is a theoretical concern.
• Unknown modification effects: The acetylation and amidation modifications could theoretically alter the side effect profile compared to native Semax. No data exists to confirm or rule this out.
• Semax safety record: The parent compound Semax has been used pharmaceutically in Russia since 1994 with reports of generally good tolerability. Whether this safety record transfers to the modified NA form is unconfirmed.

Half-Life

Native Semax has a relatively short half-life, estimated at minutes when administered without modification. The N-acetylation and C-amidation in NA-Semax are specifically designed to extend this duration by protecting against exopeptidase degradation at both termini.

Exact pharmacokinetic data for NA-Semax has not been published. The expected half-life extension from these modifications is modest — likely extending functional activity to the range of hours rather than minutes — based on analogous peptide modification data in the literature.

Limits of Current Evidence

• No dedicated NA-Semax studies: Essentially all evidence is borrowed from the parent Semax literature. NA-Semax has not been independently characterised in published research.
• Modification effects unknown: Whether N-acetylation and C-amidation alter efficacy, selectivity, or side effect profile compared to native Semax is entirely uncharacterised.
• No pharmacokinetic data: The presumed half-life extension has not been measured or published.
• Semax evidence limitations: Even the parent compound’s clinical evidence is predominantly from Russian sources, with limited international replication.
• Nootropic claims exceed data: NA-Semax is marketed in nootropic communities with claims that substantially exceed the available evidence, particularly regarding cognitive enhancement in healthy individuals.

Verdict

NA-Semax is essentially Semax with protective chemical modifications — acetylation and amidation — designed to improve metabolic stability. The parent compound Semax has a legitimate pharmacological pedigree as a Russian-registered pharmaceutical with decades of clinical use and a growing body of mechanistic research including novel findings on opioid receptor targeting and transcriptomic modulation.

However, NA-Semax itself has no independent research characterisation. Every claimed benefit is borrowed from Semax studies. While the chemical modifications are pharmacologically rational and well-established in peptide chemistry, assuming they produce an unambiguously superior compound without data is speculative. For researchers interested in ACTH-derived neuropeptides, the Semax literature provides the evidence base — NA-Semax adds stability engineering but zero additional efficacy data.

FAQ

What is NA-Semax amidate?

NA-Semax amidate (N-Acetyl Semax Amidate) is a chemically modified version of the peptide Semax, a synthetic analogue of ACTH(4-10). The N-acetyl group and C-terminal amide are added to improve enzymatic stability and potentially extend the peptide’s functional duration compared to unmodified Semax.

What is the difference between Semax and NA-Semax?

The difference is chemical modification: NA-Semax adds an acetyl group to the N-terminus and an amide to the C-terminus of the native Semax sequence. These protect against enzymatic degradation, theoretically extending half-life. However, no published studies directly compare their pharmacological profiles, and all efficacy claims for NA-Semax are inferred from Semax research.

Is NA-Semax a nootropic?

NA-Semax is marketed as a nootropic based on the parent compound Semax’s neuroprotective and cognitive research profile, which includes BDNF upregulation and neuroprotective gene modulation. However, no dedicated cognitive enhancement studies have been conducted with NA-Semax specifically, and Semax’s own clinical nootropic evidence is primarily from Russian sources.

What are NA-Semax side effects?

No dedicated safety data exists for NA-Semax. Side effect expectations are based on the parent compound Semax, which has been used pharmaceutically in Russia since 1994 with reports of generally good tolerability. Common theoretical concerns include nasal irritation (if administered intranasally) and potential HPA axis effects.

How does NA-Semax compare to Selank?

Both are synthetic peptides developed in Russia for neurological applications. Semax (and by extension NA-Semax) derives from ACTH(4-10) and is primarily studied for neuroprotection and cognitive enhancement. Selank derives from tuftsin and is primarily studied for anxiolytic and anti-anxiety effects. They target overlapping but distinct neurological domains.

Is NA-Semax approved for medical use?

No. NA-Semax is not approved for medical use in any country. The parent compound Semax is registered as a pharmaceutical in Russia for neurological indications, but this regulatory status does not extend to the NA-modified analogue.

References

1. Radchenko AI. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model. Acta Naturae. 2025. PMID: 41479572
2. Giri S, et al. Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases. Neuropeptides. 2025. PMID: 41004910
3. Filippenkov IB, et al. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke. Biomedicines. 2024. PMID: 39767736
4. Filippenkov IB, et al. Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain. Genes. 2023. PMID: 37510287
5. Kolbaev SN. The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons. Bull Exp Biol Med. 2025. PMID: 41171324
6. Liu R, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury. Br J Pharmacol. 2025. PMID: 40692165
7. Inozemtseva LS, et al. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II. Eur J Pharmacol. 2024. PMID: 39442746